Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
An increasingly cost-conscious US health care landscape has placed substantial downward pressure on the large, yet contracting US IC device market. However, continuing innovation, alongside rising procedure volumes, particularly for complex CAD cases, will mitigate overall market declines and fuel revenue expansion in certain segments, including CTO-specific accessory devices as well as intravascular imaging catheters and pressure guidewires.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in the US, with market projections across a 10-year period.
The lucrative US coronary stent market saw the launch of a number of flagship DES and innovative BMS devices between 2017 and 2018.
How have market dynamics between major competitors in the DES and BMS markets changed in 2018?
What factors are driving the uptake of the newest generation of DES?
What successful strategies are competitors employing to promote sales of their newest devices in this highly competitive market?
What are some emerging technologies and competitors in the coronary stent market?
The CMS announced numerous proposed changes to reimbursement rules that stand to impact the US IC device market.
How will these proposed rules influence changes in site of service for PCI procedures?
What strategies can competitors employ to to respond to the imminent shifts in the US health care landscape?
Emerging technologies such as FFRCT, resting-state FFR, and angiography-based FFR will influence the IC diagnostic landscape in the US.
How will the adoption of FFRCT alter patient and procedure compositions in cardiac catheterization labs?
How will the emergence of alternative FFR modalities affect the FFR pressure guidewire market?
Already a Client? Log in to access this report.
Michael Tian is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional cardiology and vascular access device markets. Michael holds a in Physiology and Neuroscience from the University of Toronto.